130 related articles for article (PubMed ID: 10828687)
21. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861.
Jakse G; Hall R; Bono A; Höltl W; Carpentier P; Spaander JP; van der Meijden AP; Sylvester R
Eur Urol; 2001 Aug; 40(2):144-50. PubMed ID: 11528191
[TBL] [Abstract][Full Text] [Related]
22. Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results.
Linn JF; Black P; Derksen K; Rübben H; Thüroff JW
Eur Urol; 2000; 37 Suppl 3():34-40. PubMed ID: 10828685
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
Ovesen H; Horn T; Steven K
J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
Steinberg G; Bahnson R; Brosman S; Middleton R; Wajsman Z; Wehle M
J Urol; 2000 Mar; 163(3):761-7. PubMed ID: 10687972
[TBL] [Abstract][Full Text] [Related]
25. Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial.
Lammers RJ; Witjes WP; Janzing-Pastors MH; Caris CT; Witjes JA
J Clin Oncol; 2012 Jun; 30(18):2273-9. PubMed ID: 22585689
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study.
Jurincic CD; Engelmann U; Gasch J; Klippel KF
J Urol; 1988 Apr; 139(4):723-6. PubMed ID: 3127600
[TBL] [Abstract][Full Text] [Related]
27. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
28. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.
Losa A; Hurle R; Lembo A
J Urol; 2000 Jan; 163(1):68-71; discussion 71-2. PubMed ID: 10604316
[TBL] [Abstract][Full Text] [Related]
29. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
30. [Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study].
Kälble T; Möhring K; Ikinger U; Riedasch G; Staehler G
Urologe A; 1991 Mar; 30(2):118-21. PubMed ID: 2058066
[TBL] [Abstract][Full Text] [Related]
31. Long term follow-up of intravesical Bacillus Calmette-Guerin for the treatment of bladder transitional cell carcinoma.
Leblanc B; Duclos AJ; Bénard F; Valiquette L; Paquin JM; Lapointe S; Mauffette F; Pharand D; Faucher R; Drouin G; Perreault JP
Can J Urol; 2000 Feb; 7(1):944-8. PubMed ID: 11121250
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG.
Mugiya S; Ozono S; Nagata M; Takayama T; Ito T; Maruyama S; Hadano S; Nagae H
Jpn J Clin Oncol; 2005 Jul; 35(7):395-9. PubMed ID: 15976065
[TBL] [Abstract][Full Text] [Related]
33. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
34. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC; Steinberg GD
J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
[TBL] [Abstract][Full Text] [Related]
35. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Taylor JH; Davis J; Schellhammer P
Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
[TBL] [Abstract][Full Text] [Related]
36. Keyhole-limpet hemocyanin immunotherapy in the bilharzial bladder: a new treatment modality? Phase II trial: superficial bladder cancer.
Wishahi MM; Ismail IM; Ruebben H; Otto T
J Urol; 1995 Mar; 153(3 Pt 2):926-8. PubMed ID: 7853576
[TBL] [Abstract][Full Text] [Related]
37. A 2-week maintenance regimen of intravesical instillation of bacillus Calmette-Guerin is safe, adherent and effective in patients with non-muscle-invasive bladder cancer: a prospective, multicenter phase II clinical trial.
Kanagawa Urological Research Group (KURG)
Jpn J Clin Oncol; 2012 Sep; 42(9):813-9. PubMed ID: 22761255
[TBL] [Abstract][Full Text] [Related]
38. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
39. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
40. [Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?].
Yamada Y; Hara I; Kumano M; Furukawa J; Yamanaka K; Kamidono S
Hinyokika Kiyo; 2005 Aug; 51(8):539-43. PubMed ID: 16164270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
